↓ Skip to main content

Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management

Overview of attention for book
Attention for Chapter 9: Personalized Therapy of Small Cell Lung Cancer.
Altmetric Badge

Mentioned by

twitter
1 tweeter

Citations

dimensions_citation
5 Dimensions

Readers on

mendeley
36 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Chapter title
Personalized Therapy of Small Cell Lung Cancer.
Chapter number 9
Book title
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management
Published in
Advances in experimental medicine and biology, December 2015
DOI 10.1007/978-3-319-24932-2_9
Pubmed ID
Book ISBNs
978-3-31-924931-5, 978-3-31-924932-2
Authors

Schneider, Bryan J, Kalemkerian, Gregory P, Bryan J. Schneider M.D., Gregory P. Kalemkerian M.D., Bryan J. Schneider, Gregory P. Kalemkerian

Editors

Aamir Ahmad, Shirish M. Gadgeel

Abstract

Small cell lung cancer (SCLC) is an aggressive, poorly differentiated neuroendocrine carcinoma with distinct clinical, pathological and molecular characteristics. Despite robust responses to initial chemotherapy and radiation, the prognosis of patients with SCLC remains poor with an overall 5-year survival rate of less than 10 %. Despite the fact that numerous molecularly targeted approaches have thus far failed to demonstrate clinical utility in SCLC, further advances will rely on better definition of the biological pathways that drive survival, proliferation and metastasis. Recent next-generation, molecular profiling studies have identified many new therapeutic targets in SCLC, as well as extreme genomic instability which explains the high degree of resistance. A wide variety of anti-angiogenic agents, growth factor inhibitors, pro-apoptotic agents, and epigenetic modulators have been evaluated in SCLC and many studies of these strategies are on-going. Perhaps the most promising approaches involve agents targeting cancer stem cell pathways and immunomodulatory drugs that interfere with the PD1 and CTLA-4 pathways. SCLC offers many barriers to the development of successful therapy, including limited tumor samples, inadequate preclinical models, high mutational burden, and aggressive tumor growth which impairs functional status and hampers enrollment on clinical trials.

Twitter Demographics

The data shown below were collected from the profile of 1 tweeter who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 36 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 36 100%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 8 22%
Researcher 6 17%
Other 4 11%
Student > Doctoral Student 4 11%
Student > Master 4 11%
Other 7 19%
Unknown 3 8%
Readers by discipline Count As %
Medicine and Dentistry 17 47%
Biochemistry, Genetics and Molecular Biology 5 14%
Agricultural and Biological Sciences 2 6%
Immunology and Microbiology 2 6%
Nursing and Health Professions 1 3%
Other 3 8%
Unknown 6 17%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 December 2015.
All research outputs
#7,256,369
of 8,394,790 outputs
Outputs from Advances in experimental medicine and biology
#1,854
of 2,526 outputs
Outputs of similar age
#261,579
of 315,893 outputs
Outputs of similar age from Advances in experimental medicine and biology
#450
of 629 outputs
Altmetric has tracked 8,394,790 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 2,526 research outputs from this source. They receive a mean Attention Score of 3.4. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 315,893 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 629 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.